SFY - Verona Pharma: Key Inflection Point Directly Ahead
2024-05-23 13:23:32 ET
Summary
- Verona Pharma plc stock has lost most of its gains from a strong rally late last year.
- However, the company has a pivotal FDA decision coming up next month around its primary candidate Ensifentrine.
- Verona has secured necessary funding to support commercialization, and the analyst firm community is universally positive on the company's prospects.
- An updated analysis around Verona Pharma follows in the paragraphs below.
Today, we put Verona Pharma plc ( VRNA ) back in the spotlight. We last looked at this London-headquartered biopharma in mid-summer of last year after the stock has had a strong rally. The shares have since pilfered away most of those gains. However, the company has a pivotal FDA decision on the horizon next month, making this a good time to peak back in on Verona. An updated analysis follows below....
Verona Pharma: Key Inflection Point Directly Ahead